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B.C.G. TREATMENT OF PLEURAL
AND PERITONEAL TUMOUR
GROWTH IN RATS. M. V. PIMM.
Cancer Research Campaign Laboratories,
University of Nottingham.
Growth of intrapleurally injected cells of
immunogenic 3-methylcholanthrene induced
rat sarcomata was suppressed by intrapleural
injection of viable or radiation sterilized
B.C.G. organisms. As little as 10 ,tg of
B.C.G. was effective and treatment was
successful even if given several days after
tumour challenge. B.C.G. administered in-
travenously or subcutaneously was without
influence on pleural tumour growth. Simi-
larly, peritoneal growth of these sarcomata
was suppressed only by the intraperitoneal
injections of B.C.G. organisms.
In contrast, pleural or peritoneal growths
from cells of other rat tumours, which lacked
significant immunogenicity, were not con-
trolled by this type of B.C.G. treatment.
Nevertheless, these studies indicate the
potential of B.C.G. (contact) immunotherapy
for treatment of thoracic and peritoneal
tumour deposits, which might perhaps have
a clinical application, for example in the
treatment of malignant mesothelioma of the
pleura and peritoneum.
DETECTION OF TUMOUR ASSO-
CIATED EMBRYONIC ANTIGENS.
M. R. PRICE atid R. C. REES. Cancer
Research Campaign Laboratories, University
of Nottingham.
Chemically induced and spontaneously
arising rat tumours express embryonic anti-
gens, which are also demonstrable on embryo
cells taken between 14 and 16 days of
gestation. The expression of tumour asso-
ciated embryonic antigens may be a common
feature of malignant transformation since
these antigens are present on tumours which
lack demonstrable levels of tumour specific
rejection antigens. Also, unlike the tumour
rejection antigens associated with chemically
induced tumours, they show cross-reactivity,
especially between tumours of the same
histological type. This suggests that the
tumour associated embryonic antigens, which
differ from other embryonic products such as
cx-foetoprotein in being immunogenic in the
autochthonous host, may be appropriate
markers for immunodiagnostic assays. This
is further emphasized by studies to be dis-
cussed, showing that homogeneous prepara-
tions of soluble embryonic antigen can be
isolated readily from tumour cytoplasmic
fractions, indicating the possibility ofutilizing
defined reagents in immunoassays for moni-
toring circulating tumour antigen.
CORRELATION OF SERUM LEVELS
OF HEPATOMA D23 ANTIGEN, ANTI-
BODY AND IMMUNE COMPLEXES
WITH GROWTH OF TRANSPLANTED
TUMOURS. M. R. PRICE and J. G.
BOWEN. Cancer Research Campaign Labora-
tories, University of Nottingham.
Hepatoma D23 antigen has been moni-
tored in the serum of tumour bearing rats
using an antibody inhibition assay based
upon membrane immunofluorescence methods
for detecting antibody in tumour immune
sera. Simultaneously, levels of tumour
specific antibody in sera of tumour bearing
rats were analysed by their direct membrane
immunofluorescence staining with hepatoma
D23 cells. Applying these techniques, it has
been established that during the early stages
of subcutaneous growth of hepatoma D23 in
syngeneic rats there is significant shedding of
tumour specific antigen into the circulation.
This is then depressed after a period of
between 10 and 14 days tumour growth, at
which time circulating tumour specific im-
mune complexes are detectable. Finally,
antibody can be detected. These observa-
tions are relevant to current views that cell
mediated immunity to tumour cells can be
blocked by interaction ofantibody or immune
complexes with tumour cells or by antigen
inhibition of effector cells. Furthermore,
these model studies indicate the importance
of designing immunochemical assays for
diagnostic and prognostic purposes during
tumour therapy.
THE GROWTH OF SPONTANEOUS
MELANOMA ALLOGRAFTS IN
IMMUNOSUPPRESSED NEONATAL
DOGS. G. R. BETTON and L. N. OWEN.
Department ofAnimal Pathology, University
of Cambridge.
Clinical cases ofmelanoma in the dog have
provided tumour cells for transplantation as
fresh cell suspensions, cells stored in a frozen
state and tissue culture cell lines. Tumour
growth has been achieved in 18 of 36 cases
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using intravenous or subcutaneous routes in
newborn dogs under immunosuppression with
anti-lymphocyte serum. Intravenous injec-
tions of tumour cells resulted in miliary
nodules in the lungs and heart in as little as
3 weeks. Melanoma of the subcutis with
metastases in some cases followed subcuta-
neous innoculation. Regression has been
observed following cessation of ALS treat-
ment. Normal cells have not produced
tumours but melanoma cell cultures have
retained this characteristic of malignancy.
NUCLEAR PROTEIN METABOLISM
DURING ONE-DOSE URETHANE
CARCINOGENESIS. C. F. FARNSWORTH
and M. GRONOW. Department of Cancer
Res'arch, University of Leeds.
Treatment of 7-9 day old B6AF1 mice
with a single carcinogenic dose of urethane,
at 1 2 mg/g body weight resulted in an
immediate decrease in liver DNA synthesis
reaching a maximum at about 8-12 h after
injection, the rate of synthesis returning to
normal after 48 h.
Of the nuclear proteins, the non-histone
protein fraction showed a significant decrease
in specific activity 8 h after injection, and an
increase in specific activity 24 h after injec-
tion. Histone and residual proteins did not
show any significant changes.
The proteins present in the non-histone
protein fraction were analysed by isoelectric
focusing electrophoresis. The gels of treated
and control samples showed similar gel
patterns but with a much denser band
appearing in the treated sample having a pI
of 7 4.
Histone and residual protein fractions
were also analysed by electrophoresis and
showed no difference between treated and
control samples.
SOME IMMUNOLOGICAL PARA-
METERS IN RELATION TO PROG-
NOSIS IN PATIENTS WITH CARCI-
NOMA OF THE BRONCHUS. H. M.
ANTHONY and J. A. KIRK. Department of
Cancer Research, University of Leeds, K. E.
MADSON, M. K. MASON and G. H. TEMPLE-
MAN. Killingbeck Hospital, Leeds.
The strength ofDHS skin test response to
Candida albicans, mumps and Old Tuberculin
have been usedto assess the effector reactivity
of the immune system in patients with newly
diagnosed carcinoma of the bronchus. Signi-
ficant positive correlations were found
between the strength ofskin test response and
length of survival, symptom pattern on
diagnosis and general condition on diagnosis.
Most surviving patients retested at 6 months
showed the same strength of skin test re-
sponse in spite of deterioration of general
condition, indicating that immune com-
petence determines general condition rather
than vice versa (Cancer N. Y., in the press).
Studies of T and B lymphocyte popula-
tions in peripheral blood using resetting
techniques identifying 97% of cells of mono-
nuclear preparations of healthy donors have
shown that survival is significantly poorer
among patients with low T lymphocytes or
increased null cells at the time of diagnosis.
STUDIES RELATED TO THE CAR-
RIER PRINCIPLE IN THE DESIGN OF
CYTOTOXIC DRUGS. M. SZEKERKE.
Research Group for Peptide Chemistry,
Hungarian Academy of Science, Budapest.
With the aim ofrationalizing the design of
peptide-type carriers attached to cytotoxic
drugs, attention was focused on the mecha-
nism of carrier function. The interaction of
model peptides with nucleic acids was
analysed by following the thermal denatura-
tion profiles.
Complex formation with DNA reflects
adequately the differences in the anti-tumour
activity of diastereoisomer ax- and y-glutamyl
melphalan derivatives. The changes of
Tm-values of poly I: C-peptide complexes
are in marked contrast to the behaviour ofthe
complexes of DNA with the same peptides.
No differences were detected in the ultra-
violet absorption spectra (250C) of DNA in
the presence of peptides, while with N-
aminoacyl D-glucosamine derivatives inter-
actions are indicated by spectral shifts.
Both for carrier activity and DNA
interaction there seem to exist precise
structural requirements for peptides.